InMed Pharmaceuticals (INM) AI Stock Analysis

• Market Cap: $5.29M
• Dividend Yield: N/A
• Average Volume (3M): 3.86M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.73
• Revenue Growth: -12.53%
• EPS Growth: 48.59%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -1.94
• Shares Outstanding: 2,002,186
• 10 Day Avg. Volume: 213,544
• 30 Day Avg. Volume: 3,856,398
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -805.43
• Enterprise Value/Revenue: -160.99
• Enterprise Value/Gross Profit: -1.92K
• Enterprise Value/Ebitda: 109.62
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: $2.50 ▼(-5.30%Downside)

InMed Pharmaceuticals' overall stock score is primarily hindered by its financial performance and valuation concerns. The persistent operational losses and negative cash flows are significant risks. Technical analysis indicates a mildly bearish to neutral trend. The recent $5M private placement is a positive development, but it does not outweigh the broader financial challenges.

InMed Pharmaceuticals Business Overview & Revenue Model

Company Description

InMed Pharmaceuticals (INM) is a biopharmaceutical company focused on the research, development, and commercialization of novel, cannabinoid-based therapeutics. Operating within the pharmaceutical sector, InMed specializes in the manufacturing and development of rare cannabinoids and advanced cannabinoid-based treatments with a focus on various unmet medical needs.

How the Company Makes Money

InMed Pharmaceuticals generates revenue primarily through the development and commercialization of cannabinoid-based products. The company's key revenue streams include the sales of pharmaceutical-grade cannabinoids, licensing agreements, and partnerships with other pharmaceutical and biotechnology companies. InMed's proprietary IntegraSyn™ manufacturing technology contributes to its earnings by enabling the efficient synthesis of rare cannabinoids at a commercial scale, thus enhancing its product offerings and market reach. Additionally, strategic collaborations and partnerships play a significant role in expanding its revenue base by leveraging shared expertise and resources in product development and distribution.

InMed Pharmaceuticals Financial Statement Overview

Summary

InMed Pharmaceuticals faces significant financial challenges, with persistent operational losses impacting profitability and cash flow. Despite a relatively strong balance sheet with low leverage, the sustained negative earnings and cash flow trends may threaten long-term viability unless growth in revenue and operational efficiency can be achieved.

Income Statement

InMed Pharmaceuticals shows a volatile income statement with consistent losses. The company reported a significant negative gross profit margin and net profit margin in the TTM period, indicating high expenses relative to low revenues. Revenue growth is present but from a very low base, and both EBIT and EBITDA margins are substantially negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio, indicating good financial stability. However, return on equity is negative due to the persistent net losses. The equity ratio is strong, showing reliance on equity financing, but ongoing losses pose a risk to sustainability.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating that the company is not generating positive cash from its core operations. The operating cash flow to net income ratio is poor, reflecting inefficiency in converting net losses into positive cash flows. The company relies on financing activities to support its operations.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	6.29M	5.48M	1.40M	0.00	0.00
Gross Profit	1.51M	1.86M	699.85K	-197.03K	-183.09K
EBITDA	-10.30M	-10.31M	-17.10M	-9.80M	―
Net Income	-10.50M	-10.53M	-23.95M	-10.20M	-8.94M
Balance Sheet
Total Assets	11.82M	14.11M	12.79M	9.78M	7.50M
Cash, Cash Equivalents and Short-Term Investments	6.61M	8.91M	6.22M	7.41M	5.84M
Total Debt	962.66K	391.71K	793.77K	269.77K	316.28K
Total Liabilities	2.62M	2.02M	3.71M	2.40M	1.92M
Stockholders Equity	9.21M	12.09M	9.08M	7.38M	5.58M
Cash Flow
Free Cash Flow	-7.00M	-7.45M	-15.62M	-9.79M	―
Operating Cash Flow	-6.99M	-7.28M	-15.58M	-9.79M	―
Investing Cash Flow	-9.29K	-661.80K	-673.00K	-1.73K	3.62M
Financing Cash Flow	4.65M	10.68M	15.07M	10.85M	―

InMed Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INM, the sentiment is Negative. The current price of 2.64 is below the 20-day moving average (MA) of 2.84, below the 50-day MA of 2.86, and below the 200-day MA of 3.57, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 45.20 is Neutral, neither overbought nor oversold. The STOCH value of 17.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INM.

InMed Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$16.95B	5.65	-7.44%	2.87%	11.55%	-28.15%
SCNI	52 Neutral	$1.76M	0.35	138.38%	―	―	―
GRI	45 Neutral	$4.97M	―	-468.00%	―	―	98.55%
INM	40 Underperform	$5.29M	―	-91.71%	―	-12.53%	48.59%
SHPH	32 Underperform	$4.14M	―	-346.19%	―	―	-7.18%
GLMD	28 Underperform	$4.49M	―	-49.58%	―	―	71.41%
REVB	28 Underperform	$4.42M	―	-233.26%	―	―	-115.81%

InMed Pharmaceuticals Corporate Events

InMed Pharmaceuticals Secures $5M in Private Placement

On June 24, 2025, InMed Pharmaceuticals entered into a securities purchase agreement with an institutional investor for a private placement of approximately $5 million. The transaction involved the issuance of pre-funded warrants and preferred investment options, with H.C. Wainwright & Co. acting as the exclusive placement agent. The proceeds are intended to support the development of InMed’s pharmaceutical pipeline and commercial sales of rare cannabinoids through its subsidiary, BayMedica LLC.

InMed Pharmaceuticals Faces Quorum Issue at Special Meeting

InMed Pharmaceuticals held a special meeting on June 13, 2025, to approve a potential issuance of more than 20% of its common shares, as per Nasdaq rules. However, due to the lack of a quorum, no business was conducted, and the board is considering whether to reschedule the meeting or address the proposal at the annual general meeting.